Blink Device Company | 合法醫療器材資訊網

ManufacturerofmedicaldevicesintheUnitedStates.

Even today, in the era of sugammadex, residual neuromuscular blockade - also known as residual paralysis - remains a common and often overlooked cause of patient complications.

Multiple studies spanning decades have reported residual paralysis incidence rates ranging from 10 to 60%.2 Even in institutions where sugammadex is used for every reversal, the incidence of residual paralysis remains as high as 10% if neuromuscular monitoring is not used.3

Residual paralysis causes postoperative pulmonary complications at the hospitals expense.2, 4 Edwards et al. determined pulmonary complications cost Temple University Hospital roughly $7 million dollars every year. Preventing a fraction of those complications would cover the capital purchase of quantitative neuromuscular monitoring and the ongoing cost of consumables with the potential for major savings.4